

FORMULARIO UNICO DE CORRECCIONES Y MODIFICACIONES
2000-10

1

SOLICITUD DE:

☐ Corrección de Error Material

☒ Modificación a una Solicitud

2

SOLICITANTE

Nombre:

**SANOFI-AVENTIS
DEUTSCHLAND GMBH**

Dirección:

Brüningstrasse 50

Teléfono:

Fax:

E-Mail:

Domicilio:

FRANKFURT AM MAIN, ALEMANIA

IDENTIFICACIÓN

C.C.

NIT

C.E.

Otro

Número

3

REPRESENTANTE
O APODERADO

Nombre:

LUIS PATIÑO LEYVA

Dirección:

**Cra. 11ª No.94-78. Oficina 308
Bogotá, D.C., Colombia.**

Teléfono:

6161948

Fax:

6163976

E-Mail:

IDENTIFICACIÓN

C.C.

NIT

C.E.

Otro

Número

2.930.616

TP

2698

4

Numero de Expediente: **03 077714**

5

Descripción de la corrección o modificación solicitada:

Que se tenga en cuenta el cambio de nombre

de la sociedad AVENTIS PHARMA DEUTSCHLAND GMBH, domiciliada en Frankfurt am Main, Alemania, por el de **SANOFI-AVENTIS DEUTSCHLAND GMBH**, domiciliada en Frankfurt am Main, Alemania, en relación con la solicitud de patente referente a: **DERIVADOS DE IMIDAZOLIDINA, SU PREPARACIÓN, SU USO Y PREPARACIONES FARMACÉUTICAS QUE LOS CONTIENEN**. En consecuencia, el trámite de esta solicitud de patente se debe continuar a nombre de la sociedad **SANOFI-AVENTIS DEUTSCHLAND GMBH**.

6

Comprobante de pago No. **06 - 17,488**

Fecha: **Marzo 6 de 2006**

7

Anexos:

☒

Comprobante de pago de la tasa

☒

El poder con que obro. Se encuentra en el Expediente No. **05 096625**.


☒

El documento de cambio de nombre respectivo.

8

NOMBRE: **LUIS PATIÑO LEYVA**

FIRMA:



C.C. **2.930.616** Bogotá

T.P. **2698**

1662

SUPERINDUSTRIA Y COMERCIO
Radicacion : 03077714 00000004 Folios: 18
Fecha (AMD): 2006-03-14 15:40:00
Tramite : 011 PCI-PATENT 379 FASE NACI 329 COMPLEMEN
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 06 - 17,488
FECHA : MARZO 6 DE 2006

***** CONSIGNACION *****


DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
GUSTAVO HOLLMAN	CONSIGNACION	BANCO POPULAR	050-00110-6	48485284	28/02/2006	6,555,000.00

***** CONCEPTO *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-03	CAMBIO DE MODALIDAD Y MODIFICA	
		12 MARCAS Y LEMAS COMERCIALES	95,000.00
		TOTAL :	\$ 95,000.00

SON: NOVENTA Y CINCO MIL PESOS


Ref.: 55021

RESPONSABLE : 

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

->Dieser Ausdruck wird nicht unterschrieben und gilt als beglaubigte Abschrift<-


Nummer der Eintragung	a) Firma b) Sitz, Niederlassung, Zweigniederlassungen c) Gegenstand des Unternehmens	Grund- oder Stammkapital	a) Allgemeine Vertretungsregelung b) Vorstand, Leitungsorgan, geschäftsführende Direktoren, persönlich haftende Gesellschafter, Geschäftsführer, Vertretungsberechtigte und besondere Vertretungsbefugnis	Prokura	a) Rechtsform, Beginn, Satzung oder Gesellschaftsvertrag b) Sonstige Rechtsverhältnisse	a) Tag der Eintragung b) Bemerkungen
1	2	3	4	5	6	7
1	a) <u>Aventis Pharma Deutschland GmbH</u> b) Frankfurt am Main c) a) Die Produktion von pharmazeutischen Produkten in Deutschland; b) das Marketing und der Vertrieb von pharmazeutischen Produkten; c) die Entwicklung von pharmazeutischen Produkten und die Forschung in diesem Bereich.	5.201.000,00 EUR	a) Die Gesellschaft hat mindestens zwei Geschäftsführer. Die Gesellschaft wird durch zwei Geschäftsführer oder durch einen Geschäftsführer gemeinsam mit einem Prokuristen vertreten. b) Geschäftsführer: Dr. Meier, Heinz-Werner, Diplom-Mathematiker, Mannheim <u>Geschäftsführer:</u> <u>Kohl, Dieter, Diplom-Wirtschaftsingenieur, Idstein</u> <u>Geschäftsführer:</u> Dr. Wess, Günther, Diplom-Chemiker, Erlensee <u>Geschäftsführer:</u> <u>Dr. Lehnert, Rudolf, Mainz, *28.02.1951</u> <u>Geschäftsführer:</u> <u>Zündorf, Peter, Köln, *10.12.1956</u>	Gesamtprokura gemeinsam mit einem Geschäftsführer oder einem anderen Prokuristen Bender, Stefan, Eppstein, *02.09.1960 Waller, Ralf, Langen (Hessen), *28.12.1957 <u>Dr. Götte, Dieter, Wiesbaden</u> <u>Dambacher, Erich, Niederrhausen</u> Reimann, Axel, Kelkheim Dr. Schmiedel, Rainer, Kelkheim Dr. Christiansen, Christian-P., Frankfurt am Main Dr. Fleischmann, Klaus, Eschborn Dr. Richard, Frank, Kronberg im Taunus Pralßinger, Richard, Hofheim am Taunus Bergmann, Jürgen, Großkrotzenburg Schäfer, Manfred, Flörsheim am Main Willems, Arnold, Bad Camberg Arnold, Kurt Jacob, Niederdorffelden Dr. Kramer, Werner, Mainz Dr. Rösner, Manfred, Eppstein Prof. Schölkens, Bernhard, Kelkheim Senft, Mario, Kelkheim Szymoniak, Roland, Kelkheim Fuchs, Brigitte, Hofheim am Taunus Dr. Kirschbaum, Bernd, Mainz Prof. Dr. Selbert, Gerhard, Darmstadt <u>Dr. Mohr, Roland, Burgheim</u> Dr. Müller, Werner, Gensingen Eigenherr, Ekkehard, Kelkheim, *25.07.1952 Dr. Jacobi, Markus, Bad Homburg v. d. Höhe, *23.02.1962 Naumann, Christoph, Königstein im Taunus, *06.05.1955 Dr. Aretz, Werner, Königstein im Taunus, *22.09.1951 Dr. Höhn, Thomas, Köln, *03.11.1944 Dr. Stütz, Hans-Ulrich, Frankfurt am Main, *15.03.1963 Stöppler, Manfred, Niederrhausen, *04.01.1961 Dr. Mismann, Manfred Heinrich, Hofheim am Taunus, *01.12.1949 Dr. Busch, Andreas Eugen, Kelkheim, *26.08.1963 <u>Brinkmann, Stefan Wolfgang, Bad Soden am Taunus, *10.07.1966</u> Bleike, Jürgen, Liederbach, *23.06.1954 Dverhagen, Joost, Frankfurt am Main, *24.11.1946 Dr. Löw, Anila, Nürnberg, *19.03.1963 Marloff, Claudia, Frankfurt am Main, *15.08.1969	a) Gesellschaft mit beschränkter Haftung Gesellschaftsvertrag vom 30.10.1995 zuletzt geändert am 08.07.2003 b) Zwischen der Gesellschaft und der Aventis Pharma Holding GmbH (ehemals Hoechst Marion Roussel Aktiengesellschaft) in Frankfurt am Main als herrschendem Unternehmen ist am 15.12.1998 ein Beherrschungs- und Gewinnabführungsvertrag abgeschlossen, dem die Gesellschaftenversammlung durch Beschluss vom 15.12.1998 zugestimmt hat. Die Gesellschaft hat einen Aufsichtsrat.	a) 16.12.2004 Drescher b) Tag der ersten Eintragung: 14.11.1995 Dieses Blatt ist zur Fortführung auf EDV umgeschrieben worden und dabei an die Stelle des bisherigen Registerblattes getreten. Band III Blatt 23 ff. Sonderband Beherrschungs- und Gewinnabführungsvertrag vom 15.12.1998 Band I a) Blatt 49 ff. Sonderband






->Dieser Ausdruck wird nicht unterschrieben und gilt als beglaubigte Abschrift<-

Nr. der Eintragung	a) Firma b) Sitz, Niederlassung, Zweigniederlassungen c) Gegenstand des Unternehmens	Grund- oder Stammkapital	a) Allgemeine Vertretungsregelung b) Vorstand, Leitungsorgan, geschäftsführende Direktoren, persönlich haftende Gesellschafter, Geschäftsführer, Vertretungsberechtigte und besondere Vertretungsbefugnis	Prokura	a) Rechtsform, Beginn, Satzung oder Gesellschaftsvertrag b) Sonstige Rechtsverhältnisse		a) Tag der Eintragung b) Bemerkungen
					5	6	
1		3	4	Plecher, Renate, Frankfurt am Main, *01.05.1966 Mörler, Manfred, Bad Soden am Taunus, *13.11.1958 Dr. Keuth, Volker, Pulheim, *06.04.1961 Chappell, Alan, Bad Soden am Taunus, *24.02.1949 Dr. Köhler, Michael, Gründau-Rothbergen, *16.03.1963 <u>Dr. Karoschka, Urs, Stuttgart, *14.01.1965</u> <u>Dr. Wirth, Uwe, Kleinostheim, *25.09.1959</u> <u>Dr. Laux, Rainer, Großhobach, *28.08.1960</u> Ulrich, Dirk, Kalkheim, *26.11.1966 <u>Dr. Braun, Matthias, Hochheim am Main, *12.08.1963</u> Heint, Angelika, Bad Soden am Taunus, *08.07.1965 Dr. Wein, Elmar-Michael, Niedernhausen, *28.09.1954 Koch, Peter, Pulheim, Stommeln, *15.01.1962 Breault, Giles, Lörrach, *05.07.1955 Denizet, Alain, Bad Soden am Taunus, *13.08.1960 <u>Dr. Foersch, Manfred, Hünstetten-Wallrabenstein, *15.09.1945</u> <u>Dr. Götz, Jürgen, Bad Soden am Taunus, *04.01.1964</u> Herzog, Ute, Frankfurt am Main, *16.08.1968 Dr. Jamin, Rainer, Frankfurt am Main, *23.05.1949 <u>Dr. Konz, Elmar, Kelkheim, *03.03.1944</u> Krauß, Manuel, Liederbach, *22.07.1967 Dr. Siawert, Martin, Frankfurt am Main, *23.04.1958 Rauh, Werner, Seligenstadt (Hessen), *15.10.1951 Weil, Gabriele, Gau-Bischofsheim, *14.04.1956 Klein, Dorothea, Kelkheim, *24.04.1961 Schmitt, Michael, Buderheim, *18.12.1960 Kammerer, Matthias, Eppstein, *09.09.1966 Dr. Schuster, Peter, Sulzbach, *24.04.1951 Coenenberg, Oliver, Frankfurt am Main, *25.05.1968 Wiese, Carsten, Taunusstein, *16.02.1961 Patel, Meera, Berlin, *24.12.1984	5		
2				<u>Prokura erteilt:</u> <u>Dr. Mohr, Roland, Burghaun</u> Gesamtprokura gemeinsam mit einem Geschäftsführer oder einem anderen Prokuristen: Dr. Enhsen, Alfons, Büllborn, *22.01.1958 Dr. Kuttar, Jürgen, Kalkheim, *18.05.1953			a) 20.12.2004 Dingas-Kröl
3							05.01.2005




->Dieser Ausdruck wird nicht unterschrieben und gilt als beglaubigte Abschrift-

Nummer der Eintragung	a) Firma b) Sitz, Niederlassung, Zweigniederlassungen c) Gegenstand des Unternehmens	Grund- oder Stammkapital	1) Allgemeine Verordnungsregelung Vorstand, Leitungsorgan, geschäftsführende Direktoren, persönlich haftende Gesellschafter, Geschäftsführer, Vertretungsberechtigte und besondere Vertretungsbefugnis	Pr.	a) Rechtsform, Beginn, Satzung oder Gesellschaftsvertrag b) Sonstige Rechtsverhältnisse	a) Tag der Eintragung b) Bemerkungen
1	2	3	4	5	6	7
6				Prokura erteilt: Wiese, Carsten, Taunusstein, *16.02.1961 Prokura erteilt: Dr. Laux, Rainer, Großholbach, *28.08.1960		22.02.2005 Berend
7				Gesamtprokura gemeinsam mit einem Geschäftsführer oder einem anderen Prokuristen: Dewitz, Volker, Frankfurt am Main, *03.09.1950 Dr. Golombowski-Daffner, Sidonie, Vechel, *21.09.1964		28.02.2005 Berend b) Eintragung lfd. Nr. 5 von Amts wegen berichtigt
8				Prokura erteilt: Breault, Gilles, Lörsch, *05.07.1956		a) 05.04.2005 Dinges-Kröl
9				Prokura erteilt: Dr. Konz, Elmar, Kelkheim, *03.03.1944		11.04.2005 Dinges-Kröl
10			b) Nicht mehr Geschäftsführer: Zündorf, Peter, Köln, *10.12.1956 Bestellt als Geschäftsführer: Dr. Wessely, Jean-Yves, Berlin, *27.05.1951			a) 18.04.2005 Dinges-Kröl
11				Gesamtprokura gemeinsam mit einem Geschäftsführer oder einem anderen Prokuristen: Wirz, Edgar, Berlin, *09.08.1965 Mathes, Karsten, Berlin, *28.02.1969 Dr. Kruse, Dirk, Bad Homburg v. d. Höhe, *06.01.1958		28.04.2005 Dinges-Kröl
12				Prokura erteilt: Dr. Busch, Andreas Eugen, Kelkheim, *26.08.1963		30.05.2005 Dinges-Kröl
13				Gesamtprokura gemeinsam mit einem Geschäftsführer oder einem anderen Prokuristen: Schröder, Kai, Mülheim am Main, *13.07.1967 Dasse, Thomas, Berlin, *04.08.1968		16.06.2005 Dinges-Kröl



6
126



->Dieser Ausdruck wird nicht unterschrieben und gilt als beglaubigte Abschrift<-						
Nummer der Eintragung	a) Firma b) Sitz, Niederlassung, Zweigniederlassungen c) Gegenstand des Unternehmens	Grund- oder Stamm	a) Allgemeine Vertretungsregelung b) Vorstand, Leitungsorgan, geschäftsführende Direktoren, persönlich haftende Gesellschafter, Geschäftsführer, Vertretungsberechtigte und besondere Vertretungsbefugnis	Prokura	a) Rechtsform, Beginn, Satzung oder Gesellschaftsvertrag b) Sonstige Rechtsverhältnisse	a) Tag der Eintragung b) Bemerkungen
1	2	3	4	5	6	7
14	a) Sänhof-Aventis Deutschland GmbH			Dr. Müller-Jakic, Barbara, Bad Soden am Taunus, *02.09.1965 Dr. Rußwurm, Regine, Alsbach-Hähnlein, *14.07.1953		
15					a) Die Gesellschafterversammlung vom 28.07.2005 hat eine Änderung des Gesellschaftsvertrages in § 1 Abs.1 (Firma) beschlossen. b) Anmeldung Blatt 160 ff. Sonderband III	a) 01.09.2005 Fink-Zinnhardt b) 21.09.2005 Leifert
16		b) Nicht mehr Geschäftsführer: Dr. Lehnert, Rudolf, Mainz, *28.02.1951 Bestellt als Geschäftsführer: Dr. Braun, Matthias, Hochheim am Main, *12.08.1963 Bestellt als Geschäftsführer: Dr. Siewert, Martin, Kronberg im Taunus, *23.04.1958	Prokura erloschen: Dr. Gölte, Dieter, Wiesbaden	Prokura erloschen: Dr. Braun, Matthias, Hochheim am Main, *12.08.1963 Prokura erloschen: Lange, Wilfried, Berlin, *27.07.1952 Prokura erloschen: Dr. Siewert, Martin, Frankfurt am Main, *23.04.1958 Gesamiprokura gemeinsam mit einem Geschäftsführer oder einem anderen Prokuristen: Bach, Flavia, Bad Homburg v. d. Höhe, *06.07.1969 Gätzheid, Valentin Georg, Marburg, *18.04.1946 Dr. Jordan, Birgit, Hattersheim am Main, *28.06.1956 Dr. Lehnert, Rudolf, Mainz, *28.02.1951 Malphettes, Stephanie, Berlin, *01.04.1974 Dr. Pacl, Harald, Buseck, *20.04.1967		a) 21.09.2005 Leifert
17		b) Geschäftsführer: Kohl, Dieter, Idstein, *29.11.1944	Prokura erloschen: Brinkmann, Stefan Wolfgang, Bad Soden am Taunus, *10.07.1966 Prokura erloschen: Dr. Karkoschka, Urs, Stuttgart, *14.01.1965 Prokura erloschen: Dr. Foersch, Manfred, Hünstein-Wallrabenstein, *15.09.1945	Prokura erloschen: Brinkmann, Stefan Wolfgang, Bad Soden am Taunus, *10.07.1966 Prokura erloschen: Dr. Karkoschka, Urs, Stuttgart, *14.01.1965 Prokura erloschen: Dr. Foersch, Manfred, Hünstein-Wallrabenstein, *15.09.1945		a) 10.10.2005 Dinges-Kridl



-> Dieser Ausdruck wird nicht unterschrieben und gilt als beglaubigte Abschrift<-

Dieser Ausdruck wird nicht unterschrieben und gilt als beglaubigte Abschrift									
Nummer der Eintragung	a) Firma b) Sitz, Niederlassung, Zweigniederlassungen c) Gegenstand des Unternehmens	Grund- oder Stammkapital	a) Allgemeine Vertretungsregelung b) Vorstand, Leitungsorgan, geschäftsführende Direktoren, persönlich haftende Gesellschafter, Geschäftsführer, Vertretungsberechtigte und besondere Vertretungsbefugnis		Prokura	a) Rechtsform, Beginn, Satzung oder Gesellschaftsvertrag b) Sonstige Rechtsverhältnisse		a) Tag der Eintragung b) Bemerkungen	
1	2	3	4		5	6		7	

Frankfurt am Main, 11.10.2005
Der Ausdruck bezeugt den Inhalt des Handelsregisters
Amtliches Verzeichniss
Urkundsbekräftigung der Geschäftsstelle





9
173

El Notario Cuarto del Circuito de
Bogotá hace constar que esta foto-
copia coincide con el original de un
documento que se encuentra a la vista

13 MAR 2006



GILBERTO CASTRO CASTRO
NOTARIO CUARTO

Die wörtliche Übereinstimmung der vorstehenden Abschrift mit der mir vorliegenden beglaubigten Abschrift beglaubige ich hiermit. Die Abschrift besteht aus 7 Blättern.

Frankfurt am Main, 21. Oktober 2005

I herewith certify that the foregoing copy is a true copy of the certified copy which has been presented to me. The copy consists of 7 sheets.

Frankfurt am Main, 21 October, 2005



Dr. Oleg de Lousanoff
Dr. Oleg de Lousanoff
Notar



APOSTILLE

(Convention de la Haye du 5 octobre 1961)

- 1. Land: Bundesrepublik Deutschland
Diese öffentliche Urkunde
- 2. ist unterschrieben von Dr. de Lousanoff
- 3. in seiner Eigenschaft als amtlich bestellter Notar
- 4. sie ist versehen mit dem Siegel/Stempel des(der) Notars

Bestätigt

- 5. in Frankfurt/Main
- 6. am 26.10.05
- 7. durch den Herrn Präsidenten des Landgerichts
- 8. unter Nr. 91 Ea A 8466
- 9. Siegel/Stempel
- 10. Unterschrift



Frank
i.V. Franke

11
178


Registro Comercial B
Juzgado Municipal de Frankfurt am Main

Número de la compañía: HRB 40661

Esta impresión no se firma y es válida como copia autenticada

Impresión Oficial

Copia del 11.10.2005 9:39



Entrada No. 1:

Razón social: Aventis Pharma Deutschland GmbH

Domicilio: Frankfurt am Main

Objeto de la empresa:

- a) la producción de productos farmacéuticos en Alemania;
- b) el mercadeo y la venta de productos farmacéuticos;
- c) el desarrollo de productos farmacéuticos y la investigación en este campo

Capital social o nominal: 5.201.000,00 EUROS

Reglamentación general de representación:

La sociedad tiene por lo menos dos gerentes.

La sociedad es representada por dos gerentes o por un gerente conjuntamente con un apoderado.

Gerentes:

Dr. Meier, Heinz-Werner, Matemático Diplomado, Mannheim

Kohl, Dieter, Ingeniero Económico Diplomado, Idstein

Dr. Wess, Günther, Químico Diplomado, Erlensee

Dr. Lehnert, Rudolf, Mainz, *28.02.1951

Zündorf, Peter, Colonia, *10.12.1956

Apoderados:

Poder colectivo conjuntamente con un gerente o con otro apoderado:

Bender, Stefan, Eppstein, *02.09.1960

Walter, Ralf, Langen (Hessen), *26.12.1957

Dr. Götter, Dieter, Wiesbaden

Dambacher, Erich, Niedernhausen

Raimann, Axel, Kelkheim,

Dr. Schmiedel, Rainer, Kelkheim


Dr. Christiansen, Christian-P, Frankfurt am Main

Dr. Fleischmann, Klaus, Eschborn


Dr. Richard, Frank, Krinberg im Taunus,

Preißinger, Richard, Hofheim am Taunus

Bergmann, Jürgen, Großkrotzenburg
 Schäfer, Manfred, Flörsheim am Main,
 Willems, Arnold, Bad Camberg
 Arnold, Kurt Jakob, Niederdorffelden
 Dr. Kramer, Werner, Mainz,
 Dr. Rösner, Manfred, Eppstein
 Prf. Schölken, Bernward, Kelkheim
 Senft, Mario, Kelkheim
 Szymoniak, Roland, Kelkheim
 Fuchs, Brigitte, Hofheim am Taunus
 Dr. Kirschbaum, Bernd, Mainz, Prof.
 Dr. Selbert, Gerhard, Darmstadt
Dr. Mohr, Roland, Burghaun
Dr. Müller, Werner, Gensingen
 Eigenherr, Ekkhard, Kelkheim, *25.07.1952
 Dr. Jakobi, Markus, Bad Homburg v.d.Höhe, *23.02.1962
 Naumann, Christoph, Königstein im Taunus, *06.05.1955
 Dr. Aretz, Werner, Königstein im Taunus, *22.09.1951
Dr. Högn, Thomas, Colonia, *03.11.1944
 Dr. Stilz, Hans-Ulrich, Frankfurt am Main, *15.03.1963
 Stoppler, Hanfried, Niedernhausen, *04.01.1961
 Dr. Milsmann, Manfred Heinrich, *Hofheim am Taunus, *01.12.1949
Dr. Busch, Andreas Eugen, Kelkheim, *26.08.1963
Brinkmann, Stefan Wolfgang, Bad Soden Am Taunus, *10.07.1966
 Bieke, Jürgen, Liederbach, *23.06.1954
 Dwerhagen, Jost, Frankfurt am Main, *24.11.1946
 Dra. Löw, Anita, Nürnberg, *19.03.1953
 Marloff, Claudia, Frankfurt am Main, *15.08.1969
 Plecher, Renate, Frankfurt am Main, *01.05.1966
 Mörlner, Manfred, Bad Soden am Taunus, *13.11.1958
 Dr. Keuth, Volker, Pulheim, *06.04.1961
 Chapell, Alan, Bad Soden am Taunus, *24.02.1949
 Dr. Köhler, Michael, Gründau-Rothenbergen, *16.03.1963
Dr. Karkoschka, Urs, Stuttgart, *14.01.1965
 Dr. Wirth, Uwe, Kleinostheim, *25.09.1959
Dr. Laux, Reiner, Großholbach, *28.08.1960
 Ulrich, Dirck, Kelkheim, *26.11.1966
Dr. Braun, Matthias, Hochheim am Main, *12.08.1963
 Heintl, Angelika, Bad Soden am Taunus, *08.07.1965
 Dr. Wein, Elmar-Michael, Niedernhausen, *28.09.1954
 Koch, Peter, Pulheim, Stommeln, *15.01.1962
Breault, Giles, Lörrach, *05.07.1956



Denizet, Alain, Bad Soden am Taunus, *13.08.1960
Dr. Foersch, Manfred, Hünstteten-Wallrabenstein, *15.09.1945
Dr. Götz, Jürgen, Bad Soden am Taunus, *04.01.1964
 Herzog, Ute, Frankfurt am Main, *16.08.1968
 Dr. Jamin, Rainer, Frankfurt am Main, *23.05.1949
Dr. Konz, Elamr, Kelkheim, *03.03.1944
 Krauß, Manuel, Liederbach, *27.07.1967
Dr. Siewert, Martin, Frankfurt am Main, *23.04.1958
 Rauh, Werner, Seligenstadt (Hessen), *15.10.1951
 Welt, Gabriele, Gau-Bischofsheim, *14.04.1956
Klein, Dorothea, Kelkheim, *24.04.1961
 Schmitt, Michael, Buddenheim, *18.12.1960
 Kammerer, Matthias, Eppstein, *09.09.1966
 Dr. Schuster, Peter, Sulzbach, *24.04.1951
 Coenenberg, Oliver, Frankfurt am Main, *26.05.1968
 Wiese, Carsten, Taunusstein, *16.02.1961
 Patel, Meera, Berlín, 24.12.1964



Condiciones legales:

a) Sociedad con responsabilidad limitada.

Contrato de sociedad del 30.10.1995 modificado por última vez el 08.07.2003

b) Entre la sociedad y la compañía Aventis Pharma Holding GmbH (anteriormente llamada Hoechst Marion Roussel Aktiengesellschaft) domiciliada en Frankfurt am Main como empresa dominante se celebró un Contrato de Dominación y Extracción de Ganancias el 15.12.1998, el cual fue aprobado por la asamblea de socios mediante resolución el 15.12.1998.

La sociedad tiene un consejo de vigilancia.

Fecha de la entrada y firma: 16.12.2004 Drescher

Observaciones:

Fecha de la primera entrada: 14.11.1995

Esta hoja ha sido redactada de nuevo para su continuación mediante procesamiento por medios electrónicos y reemplaza la hoja de registro llevada hasta el presente.

Entrada No. 2:

Apoderados: Ha caducado el poder de Dr. Mohr, Roland, Burghaun

Poder colectivo conjuntamente con un gerente o con otro apoderado:

Dr. Enhsen, Alfons, Büttelborn, *22.01.1958

Dr. Kutter, Jürgen, Kelkheim, *18.05.1953

Fecha de la entrada y firma; 20.12.2004 Dinges-Król

Entrada No. 3:

Poder colectivo conjuntamente con un gerente o con otro apoderado:
 Bialojahn, Ulf, Wisbaden, *09.12.1962

Fecha de la entrada y firma: 01.05.2005 Dinges-Kröl

Entrada No. 4:

Apoderados:

Han caducado los poderes de:

Dr. Christianse, Chistian-P, Frankfurt am Main

Dr. Götz, Jürgen, Bad Soden am Taunus, *04.01.1961

Klein, Dorothea, Kelkheim, *24.04.1961

Dr. Högn, Thomas, Colonia, *03.11.1944

Poder colectivo conjuntamente con un gerente o con otro apoderado:
 Dr. Hemrich, Hans Thomas, Kelkheim, *25.10.1961

Fecha de la entrada: 28.01.2005 Dinges-Kröl

Entrada No. 5:

Apoderados:

Poder colectivo conjuntamente con un gerente o con otro apoderado:
 Dr. Riederer, Heinrich Jacob, Neubiberg, *18.07.1951

Koch, Klaus, Berlín, *23.04.1958

Henn, Miriam, Frankfurt am Main, *03.05.1971

Dr. Kahl, Thomas, Hofheim am Taunus, *27.06.1961

Dewitz, Volker, Frankfurt am Main, *09.09.1950

Dr. Suermondt, Matthias, Berlín, *26.07.1960

Dr. Stanzz, Christian, *Berlín, *16.11.1962

Pulmann, Heinrich, Munich, *11.10.1948

Müller, Hans, Gröbenzell, *08.02.1950

Martins, Yvonne, Puchheim, *28.05.1968

Luck, Fred, Berlín, *10.11.1962

Lange, Wilfried, Berlín, *27.07.1952

Kress, Stephen, Kleinmachnow, *15.11.1956

Dr. Hundt, Ferdinand, *23.04.1949

Hirtz, Christophe, Berlín, *03.12.1965

Dr. Heinemann, Christoph, Frankfurt am Main, *28.12.1969

Haser, Manfred, Berlín, *27.09.1962


Dr. Greive, Heinrich, Sulzbach, *05.06.1958

Dr. Golombowski-Daffner, Sidonie, Eching, *21.09.1964

Döppler, Stephen, Berlín, *23.08.1947

Carels, Jan, Berlín, *26.12.1968

Fecha de la entrada: 18.02.2005 Dinges-Kröl



Entrada No. 6:

Apoderados:

Poder caducado: Wiese, Carsten, Taunusstein, *16.02.1961Poder caducado: Dr. Laux, Reiner, *28.08.1960

Fecha de la entrada: 22.02.2005 Berend

Entrada No. 7:

Apoderados:

Poder colectivo conjuntamente con un gerente o
Dewitz, Volker, Frankfurt am Main, *03.09.1950Dr. Golombowki-Daffner, Sidonie, *21.09.1964

Fecha de la entrada: 8.02.2005 Berend

Observaciones:

La entrada No. 5 ha sido oficialmente corregida.

Entrada No. 8:

Poderes:

Poder caducado: Brault, Gilles, Lörrach, *05.07.1956

Fecha de la entrada: 04.05.2005 Dinges-Król

Entrada No. 9:

Apoderados:

Poder caducado: Dr. Konz, Elmar, Kelkheim, *03.03.1944

Fecha de la entrada: 11.04.2005 Dinges-Król

Entrada No. 10:

Gerentes:

Ha dejado de ser gerente: Zündorf, Peter, Colonia, *10.12.1956Nombrado gerente: Dr. Wessely, Jean-Yves, Berlín, *27.05.1951

Fecha de la entrada: 18.04.2005 Dinges-Król

Entrada No. 11:

Apoderados:

Poder colectivo conjuntamente con un gerente o con otro apoderado:
Wirz, Edgar, Berlín, *09.08.1965Mathes, Karsten, Berlín, *28.02.1969Dr. Kruse, Dirk, Bad Homburg v.d.H., 06.01.1958


Fecha de la entrada: 28.04.2005 Dinges-Król

Entrada No. 12:

Apoderados:

Poder caducado: Busch, Andreas Eugen, Kelkheim, *26.08.1963

Fecha de la entrada: 30.05.2005 Dinges-Król



Entrada No. 13:

Apoderados:


Poder colectivo conjuntamente con un gerente o con otro apoderado:
Schröder, Kai, Mühlheim am Main, *13.07.1967

Dasse, Thomas, Berlín, *04.08.1968

Dra. Müller-Jakic, Barbara, Bad Soden am Taunus, *02.09.1955

Dra. Rußwurm, Regine, Alsbach-Hähnlein, *14.07.1953

Fecha de la entrada: 16.06.2005 Dinges-Kröl

**Entrada No. 14:**

Razón social: Sanofi-Aventis Deutschland GmbH

Contrato de sociedad:

La asamblea de socios del 28.07.2005 resolvió cambiar el Artículo 1 del contrato de sociedad (razón social)

Fecha de la entrada: 01.09.2005 Frink-Zinnhardt

Observaciones:

Inscripción Hoja 160 siguientes Volumen especial III

Entrada No. 15:

Apoderados:

Poder caducado: Dr. Götte, Dieter, Wiesbaden

Fecha de la entrada: 21.09.2005 Leifert

Entrada No. 16:

Gerentes:

Ha dejado de ser gerente: Dr. Lehnert, Rudolf, Mainz, *28.02.1951Ha sido nombrado gerente: Braun, Matthias, Hochheim am Main, *12.08.1963Ha sido nombrado gerente: Dr. Siewert, Martin, Kronberg im Taunus, *23.04.1958

Poderes:

Han caducado los poderes deDr. Braun, Matthias, Hochheim am Main, *12.08.1963Lange, Wilfried, Berlín, *27.07.1952Dr. Siewert, Martin, Kronberg im Taunus, *23.04.1958Poder colectivo conjuntamente con un gerente o con otro apoderado:
Bach, Flavia, Bad Homburg, v.d.H., *06.07.1969

Götzfried, Valentin Georg, Marburg, *18.04.1946

Dra. Jordan, Birgit, Hattersheim am Main, *28.06.1956

Dr. Lehnert, Rudolf, Mainz, *28.02.1951

Malphettes, Stephane, Berlin, *01.04.1974
Dr. Paci, Harald, *20.04.1967

Fecha de la entrada: 21.09.05 Leifert

Entrada No. 17:

Gerentes:


Gerente: Kohl, Dieter, Idstein, *29.11.1944

Apoderados:

Poderes caducados:

Brinkmann, Stefan Wolfgang, Bad Soden am Taunus, *10.07.1968
Dr. Karkoschka, Urs, Stuttgart, *14.01.1965
Dr. Foersch, Manfred, Hüstetten-Wallrabenstein, *15.09.1945

Fecha de la entrada: 10.10.2005 Dinges-Król



Se autentica la concordancia textual de la adjunta fotocopia con la fotocopia autenticada que he tenido a la vista. Dicha fotocopia consta de 7 hojas.

Frankfurt am Main, 21 de Octubre de 2005

Dr. Oleg de Lousanoff, Notario en Frankfurt am Main
(Firma y Sello Oficial)

APOSTILLA

(Convención de La Haya del 5 de Octubre de 1961)

1. País: República Federal de Alemania
2. Este documento público
Ha sido firmado por: Doctor de Lousanoff
3. Actuando en calidad de: Notario nombrado oficialmente
4. Y lleva el sello: Del Notario

Confirmado

5. En: Frankfurt/Main
6. El día: 26.10.05
7. Por: El Señor Presidente del Tribunal Regional
8. Bajo el No.: 91 Ea A 8466
9. Sello: EL PRESIDENTE DEL TRIBUNAL REGIONAL FRANKFURT AM MAIN
10. Firma: En representación: Franke

ADOLF WATZKE
Traductor Oficial
Res. 2433 Minjusticia

El Notario Público del Circuito de Bogotá (Bogotá) constata que esta foto es una copia calcoada del original de un documento que se le muestra la vista.

13 MAR 2006

GILBERTO CASTRO
NOTARIO CUARTO

MINISTERIO DE
RELACIONES EXTERIORES

400146

COPIA FIRMA APLICADA EN EL
DOCUMENTO DESEMPLEA
LAS FUNCIONES INDICADAS

NO SE ASUME
RESPONSABILIDAD DEL TEXTO

2005 DIC 27 P 12:04

JEFE DE LEGALIZACIONES
BOGOTÁ D.C.

DIVISION DE NUEVAS CREACIONES

RADICACIÓN EXPEDIENTE No. 03- 77714

**EL EXTRACTO DE LA PRESENTE SOLICITUD DE PATENTE DE INVENCION –
PCT, FUE PUBLICADO EN LA GACETA DE PROPIEDAD INDUSTRIAL No 546,
DE FECHA 30 DE NOVIEMBRE DE 2004, EL TERMINO HABIL SEÑALADO
POR LA LEY EXPIRA EL 24 DE FEBRERO DE 2005.**

NOTA: Dentro del plazo de los seis (6) meses siguientes a partir de la fecha de publicación en la gaceta de Propiedad Industrial, deberá solicitar y cancelar el examen de patentabilidad so pena de que la solicitud caiga en abandono, de acuerdo con lo establecido en el Artículo 44 de la Decisión 486/2000.

SE PRESENTARON OPOSICIONES POR PARTE DE TERCEROS.

SI ☐


NO ☒



(21) (A1) **2,254,420**
(22) 1998/11/17
(43) 1999/05/19

01

- (72) WEHNER, Volkmar, DE
(72) STILZ, Hans Ulrich, DE
(72) SCHMIDT, Wolfgang, DE
(72) SEIFFGE, Dirk, DE
(71) HOECHST MARION ROUSSEL DEUTSCHLAND GMBH, DE
(51) Int.Cl.⁶ C07D 233/72, A61K 31/675, C07F 9/6558, C07F 9/6506,
A61K 31/55, C07D 235/02, C07D 403/00, C07K 5/093, C07K 5/075,
A61K 38/06, A61K 38/05, A61K 31/54, A61K 31/535
(30) 1997/11/19 (19751251.8) DE
(54) **DERIVES D'IMIDAZOLIDINE DE SUBSTITUTION, LEUR
PREPARATION, LEUR UTILISATION ET PREPARATIONS
PHARMACEUTIQUES LES UTILISANT**
(54) **SUBSTITUTED IMIDAZOLIDINE DERIVATIVES, THEIR
PREPARATION, THEIR USE AND PHARMACEUTICAL
PREPARATIONS COMPRISING THEM**



(I)

(57) The present invention relates to substituted imidazolidine derivatives of the formula I, (see formula I) in which B, E, W, Y, R, R², R³, R³⁰, e and h have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use, in particular as pharmaceutical active compounds, and pharmaceutical preparations which contain compounds of the formula I.

anthryl or fluorenyl, (C₆-C₁₀)-aryl groups are, for example, 1-naphthyl, 2-naphthyl and phenyl. Biphenylyl radicals, naphthyl radicals and in particular phenyl radicals are preferred aryl radicals. Aryl radicals, in particular phenyl radicals, can be unsubstituted or monosubstituted or polysubstituted, for example monosubstituted,

5 disubstituted, trisubstituted or tetrasubstituted, by identical or different radicals. Substituted aryl radicals, in particular phenyl radicals, are preferably substituted by radicals from the group consisting of (C₁-C₈)-alkyl, in particular (C₁-C₄)-alkyl such as methyl; (C₁-C₈)-alkoxy, in particular (C₁-C₄)-alkoxy such as methoxy; (C₁-C₈)-alkoxy, in particular (C₁-C₄)-alkoxy, which is substituted by one or more fluorine atoms, for

10 example 1, 2, 3, 4 or 5 fluorine atoms, such as trifluoromethoxy; halogen; nitro; amino; trifluoromethyl; hydroxyl; hydroxy-(C₁-C₄)-alkyl such as, for example, hydroxymethyl or 1-hydroxyethyl or 2-hydroxyethyl; methylenedioxy; ethylenedioxy; formyl; acetyl; cyano; hydroxycarbonyl; aminocarbonyl; (C₁-C₄)-alkoxycarbonyl; phenyl; phenoxy; benzyl; benzyloxy; tetrazolyl. The same applies, for example to

15 substituted aryl radicals, in groups such as arylalkyl, arylcarbonyl, etc. Arylalkyl radicals are, for example, 1- and 2-naphthylmethyl, 2-, 3- and 4-biphenylmethyl and 9-fluorenylmethyl and in particular benzyl, all of which can also be substituted.

Substituted arylalkyl radicals are, for example, benzyl radicals and naphthylmethyl radicals substituted in the aryl moiety by one or more (C₁-C₈)-alkyl radicals, in

20 particular (C₁-C₄)-alkyl radicals, for example 2-, 3- and 4-methylbenzyl, 4-isobutylbenzyl, 4-tert-butylbenzyl, 4-octylbenzyl, 3,5-dimethylbenzyl, pentamethylbenzyl, 2-, 3-, 4-, 5-, 6-, 7- and 8-methyl-1-naphthylmethyl, 1-, 3-, 4-, 5-, 6-, 7- and 8-methyl-2-naphthylmethyl; benzyl radicals and naphthylmethyl radicals substituted in the aryl moiety by one or more (C₁-C₈)-alkoxy radicals, in particular

25 (C₁-C₄)-alkoxy radicals, for example 4-methoxybenzyl, 4-neopentyloxybenzyl, 3,5-dimethoxybenzyl, 2,3,4-trimethoxybenzyl; 3,4-methylenedioxybenzyl;

trifluoromethoxybenzyl radicals; nitrobenzyl radicals, for example 2-, 3- and 4-nitrobenzyl; halobenzyl radicals, for example 2-, 3- and 4-chlorobenzyl and 2-, 3-, and 4-fluorobenzyl, 3,4-dichlorobenzyl, pentafluoro-benzyl; trifluoromethylbenzyl

30 radicals, for example 3- and 4-trifluoromethylbenzyl or 3,5-bistrifluoromethylbenzyl. Substituted arylalkyl radicals, however, can also contain substituents different from

185
p3: final
store ✓

one another. In the compounds of the formula I, however, in general not more than two nitro groups can be present in the molecule.

In monosubstituted phenyl radicals, the substituent can be located in the 2-position, the 3-position or the 4-position. Disubstituted phenyl can be substituted in the 2,3-position, the 2,4-position, the 2,5-position, the 2,6-position, the 3,4-position or the 3,5-position. In trisubstituted phenyl radicals, the substituents can be situated, for example, in the 2,3,4-position, the 2,3,5-position, the 2,4,5-position, the 2,4,6-position, the 2,3,6-position or the 3,4,5-position.

The above explanations for the monovalent aryl radicals apply correspondingly to the divalent arylene radicals, i. e. divalent radicals derived from aromatics. Arylene radicals can be linked via any desired positions. An example of arylene radicals is phenylene radicals, which can be present, for example, as 1,4-phenylene or as 1,3-phenylene.

Phenylene-alkyl is in particular phenylenemethyl ($-\text{C}_6\text{H}_4-\text{CH}_2-$) or phenyleneethyl (for example $-\text{C}_6\text{H}_4-\text{CH}_2-\text{CH}_2-$), alkylene-phenyl is in particular methylenepheryl ($-\text{CH}_2-\text{C}_6\text{H}_4-$). Phenylene-alkenyl is in particular phenyleneethenyl or phenylenepropenyl.

Heteroaryl is a radical of a monocyclic or polycyclic aromatic system having 5 to 14 ring members, which contains 1, 2, 3, 4 or 5 heteroatoms as ring members.

Examples of heteroatoms are N, O and S. If several heteroatoms are contained, these can be identical or different. Heteroaryl radicals can also be unsubstituted or monosubstituted or polysubstituted, for example monosubstituted, disubstituted or trisubstituted, by identical or different radicals from the group consisting of (C_1-C_8) -alkyl, in particular (C_1-C_4) -alkyl, (C_1-C_8) -alkoxy, in particular (C_1-C_4) -alkoxy, (C_1-C_8) -alkoxy, in particular (C_1-C_4) -alkoxy, which is substituted by one or more, for example 1, 2, 3, 4 or 5, fluorine atoms, halogen, nitro, amino, trifluoromethyl, hydroxyl, hydroxy- (C_1-C_4) -alkyl such as, for example, hydroxymethyl or 1-hydroxyethyl or 2-

respect to the number of ring members and heteroatoms. However, Het additionally also comprises nonaromatic heterocycles which are completely saturated or which contain one or more double bonds in the ring system. Het can be substituted on

5 nitrogen atoms and/or carbon atoms by one or more, for example 1, 2, 3 or 4, identical or different substituents, for example by (C₁-C₈)-alkyl, in particular (C₁-C₄)-alkyl, (C₃-C₁₂)-cycloalkyl, (C₃-C₁₂)-cycloalkyl-(C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, heteroaryl, heteroaryl-(C₁-C₈)-alkyl, (C₁-C₈)-alkoxy, in particular (C₁-C₄)-alkoxy, optionally substituted phenoxy, benzyloxy, halogen, nitro, amino, (C₁-C₈)-alkylamino, di-((C₁-C₈)-alkyl)-amino, trifluoromethyl, hydroxyl, methylenedioxy, ethylenedioxy, cyano, hydroxycarbonyl, aminocarbonyl, (C₁-C₄)-alkoxycarbonyl and generally by ester groups, acyl groups, oxo, thioxo, where alkyl radicals can be monosubstituted or polysubstituted by fluorine.

15 Examples of parent structures of heterocycles from which a heteroaryl radical, the radical Het, the radical of a monocyclic or bicyclic 5-membered to 12-membered heterocyclic ring, the divalent radical of a 5-membered or 6-membered heterocycle, the heterocyclic radical representing R⁷ or a heterocyclic radical representing R¹⁶ can be derived, insofar as in the individual case they come under the respective definition, pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, 20 thiazole, isothiazole, tetrazole, pyridine, pyrazine, pyrimidine, indole, isoindole, indazole, phthalazine, quinoline, isoquinoline, quinoxaline, quinazoline, cinnoline, β -carboline and benzo-fused, cyclopenta-fused, cyclohexa-fused or cyclohepta-fused derivatives of these heterocycles.

25

Nitrogen heterocycles can also be present as N-oxides or as quaternary salts.

Radicals which can be heteroaryl or the radical of a monocyclic or bicyclic 5-membered to 12-membered heterocyclic ring are, for example, 2- or 3-pyrrolyl, 30 phenylpyrrolyl, for example 4- or 5-phenyl-2-pyrrolyl, 2- or 3-furyl, 2- or 3-thienyl, 4-imidazolyl, methylimidazolyl, for example 1-methyl-2-, -4- or -5-imidazolyl,

substituted (C₆-C₁₀)-aryl, (C₆-C₁₀)-aryl-(C₁-C₄)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl or heteroaryl-(C₁-C₄)-alkyl optionally substituted in the heteroaryl radical. A specifically preferred radical representing R^{32}

is optionally substituted (C₆-C₁₀)-aryl, in particular unsubstituted phenyl or phenyl ✓

- 5 which is substituted by one or more identical or different substituents of the substituents on aromatics indicated above. If the radical R^{32} is bonded to a sulfur atom, it preferably has a meaning other than hydrogen.

- 10 R^{33} is preferably a direct bond or a divalent (C₁-C₄)-alkylene radical, particularly preferably a direct bond or a divalent (C₁-C₂)-alkylene radical, very particularly preferably a direct bond.

- 15 R^{34} is preferably a divalent radical from the group consisting of (C₁-C₈)-alkylene, (C₅-C₁₀)-cycloalkylene, (C₆-C₁₂)-bicycloalkylene, optionally substituted (C₆-C₁₄)-arylene and optionally substituted heteroarylene, particularly preferably a divalent radical from the group consisting of (C₁-C₆)-alkylene, (C₅-C₆)-cycloalkylene, optionally substituted (C₆-C₁₀)-arylene and optionally substituted heteroarylene, very particularly preferably a divalent radical from the group consisting of (C₁-C₆)-alkylene, optionally substituted (C₆-C₁₀)-arylene and optionally substituted
- 20 heteroarylene, moreover preferably a divalent radical from the group consisting of (C₁-C₄)-alkylene and optionally substituted (C₆-C₁₀)-arylene.

- 25 R^{35} is preferably a direct bond or a divalent (C₁-C₄)-alkylene radical, particularly preferably a direct bond or a divalent (C₁-C₂)-alkylene radical, in particular a direct bond or methylene or ethylene (1,2-ethylene), very particularly preferably (C₁-C₂)-alkylene (methylene or ethylene).

R^{36} is preferably a direct bond.

- 30 (R^{31}) is preferably a divalent radical - R^{33} - R^{34} - R^{35} - R^{36} -, in which one or more of the radicals R^{33} , R^{34} , R^{35} and R^{36} have preferred meanings. Particularly preferably, R^{31}

is a divalent radical from the group consisting of (C₁-C₈)-alkylene, (C₅-C₆)-cycloalkylene, (C₅-C₆)-cycloalkylene-(C₁-C₆)-alkyl, optionally substituted (C₆-C₁₀)-arylene, (C₆-C₁₀)-arylene-(C₁-C₆)-alkyl optionally substituted in the arylene radical, optionally substituted heteroarylene, heteroarylene-(C₁-C₆)-alkyl optionally

5 substituted in the heteroarylene radical, (C₁-C₈)-alkylene-CO, optionally substituted (C₆-C₁₀)-arylene-CO, (C₆-C₁₀)-arylene-(C₁-C₆)-alkyl-CO optionally substituted in the arylene radical, optionally substituted heteroarylene-CO, heteroarylene-(C₁-C₆)-alkyl-CO optionally substituted in the heteroarylene radical, optionally substituted (C₆-C₁₀)-arylene-S(O)_n, (C₆-C₁₀)-arylene-(C₁-C₆)-alkyl-S(O)_n optionally substituted in
10 the arylene radical, optionally substituted heteroarylene-S(O)_n and heteroarylene-(C₁-C₆)-alkyl-S(O)_n optionally substituted in the heteroarylene radical, in which n is 1 or 2, and where the CO group and the S(O)_n group are bonded to the nitrogen atom in the imidazolidine ring in the formula I and, in the case of the radicals

cycloalkylenealkyl, arylenealkyl and heteroarylenealkyl, the alkyl group is bonded to
15 the nitrogen atom in the imidazolidine ring in the formula I. Very particularly preferably, R³¹ is a divalent radical from the group consisting of (C₁-C₆)-alkylene, optionally substituted (C₆-C₁₀)-arylene and (C₆-C₁₀)-arylene-(C₁-C₄)-alkyl optionally substituted in the aryl radical, where in the case of the arylenealkyl radical, the alkyl group is bonded to the nitrogen atom in the imidazolidine ring in the formula I.

20 Moreover, R³¹ is preferably a divalent radical from the group consisting of (C₁-C₆)-alkylene and (C₆-C₁₀)-arylene-(C₁-C₄)-alkyl optionally substituted in the aryl radical, in particular (C₆-C₁₀)-arylene-(C₁-C₂)-alkyl, where in the case of the arylenealkyl radical, the alkyl group is bonded to the nitrogen atom in the imidazolidine ring in the formula I. Especially preferably, R³¹ is the divalent radical

25 phenylenemethyl-C₆H₄-CH₂-, in particular the radical-(1,4-phenylene)methyl-, in which the methyl group is bonded to the nitrogen atom in the imidazolidine ring in the formula I.

If R³ is hydrogen or one of the radicals (C₁-C₁₀)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical,
30 optionally substituted heteroaryl, heteroaryl-(C₁-C₈)-alkyl optionally substituted in


the heteroaryl radical, (C₃-C₈)-cycloalkyl, (C₃-C₈)-cycloalkyl-(C₁-C₈)-alkyl, (C₆-C₁₂)-bicycloalkyl, (C₆-C₁₂)-bicycloalkyl-(C₁-C₈)-alkyl, (C₆-C₁₂)-tricycloalkyl, (C₆-C₁₂)-tricycloalkyl-(C₁-C₈)-alkyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkynyl, COOR²¹, CON(CH₃)R⁴, CONHR⁴, COOR¹⁵, CON(CH₃)R¹⁵ or CONHR¹⁵, e is preferably 0 and h is preferably 1.

5 1. If R³ is R¹¹NH, e is preferably 1 and h is preferably 0. Compounds of the formula I in which e is 0 and h is 1 form a preferred group of compounds. In these preferred compounds, the group -NR-[C(R)(R)]₆-C(R²)(R³)-[C(R)(R)]_h-E in the formula I is particularly preferably the group -NH-CH(R³)-CH₂-E.


10 Preferred compounds of the formula I are those compounds in which one or more of the radicals have preferred meanings or one specific of the preferred meanings mentioned, all combinations of preferred meanings of radicals being a subject of the present invention.

15 A particularly preferred group of compounds are compounds of the formula I in which

W is a divalent radical from the group consisting of R¹-A-C(R¹³), R¹-A-C(R¹³)=C,



where the ring systems



30 can contain one or two identical or different heteroatoms from the group consisting of N, O and S, can be saturated or monounsaturated or

- in a preferred form - is substituted by (C₁-C₆)-alkyl or (C₃-C₆)-cycloalkyl-(C₁-C₂)-alkyl, in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts.

5 A further series of especially preferred compounds includes those compounds of the formula I in which at the same time the radicals R¹³ and R¹-A- are other than hydrogen, R³⁰ is the radical R³²-NH-CO-NH-(1,4-C₆H₄)-CH₂, R³² is optionally substituted phenyl, B is a divalent methylene radical which is unsubstituted or - in a preferred form - is substituted by (C₁-C₆)-alkyl or (C₃-C₆)-cycloalkyl-(C₁-C₂)-alkyl, and the radical -N(R)-[C(R)(R)]₆-C(R²)(R³)-[C(R)(R)]_n-E in the formula I is the radical
10 -NH-CH(R³)-CH₂-E, in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts.


A further series of especially preferred compounds includes those compounds of the
15 formula I in which at the same time W is one of the divalent radicals 1,1-cyclopropylidene, 1,1-cyclopentylidene and 1,1-cyclohexylidene, which are explained in greater detail above, where the radicals derived from the 5-membered ring and from the 6-membered ring can in each case carry a doubly bonded oxygen atom as substituents, R³⁰ is the radical R³²-NH-CO-NH-(1,4-C₆H₄)-CH₂ and R³² is
20 optionally substituted phenyl, in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts.

A further series of especially preferred compounds includes those compounds of the formula I in which at the same time W is one of the divalent radicals
25 1,1-cyclopropylidene, 1,1-cyclopentylidene and 1,1-cyclohexylidene, R³⁰ is the radical R³²-NH-CO-NH-(1,4-C₆H₄)-CH₂, R³² is optionally substituted phenyl and B is a divalent methylene radical which is unsubstituted or - in a preferred form - is substituted by (C₁-C₆)-alkyl or (C₃-C₆)-cycloalkyl-(C₁-C₂)-alkyl, in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically
30 tolerable salts.

Patent claims

1. A compound of the formula I

5



in which


W is a divalent radical from the group consisting of $R^1-A-C(R^{13})$, $R^1-A-C(R^{13})=C$,

15



in which the ring systems

20



can contain one or two identical or different heteroatoms from the group

25

consisting of N, O and S, can be saturated or mono- or polyunsaturated and

can be substituted by 1, 2 or 3 identical or different substituents R^{13} and/or by

one or two doubly bonded oxygen atoms and/or sulfur atoms, and in which L is

C(R¹³) or N and in which m1 and m2 independently of one another are one of

the numbers 0, 1, 2, 3, 4, 5 and 6, but the sum $m1 + m2$ is one of the numbers

30

1, 2, 3, 4, 5 or 6;

Y is a carbonyl group, thiocarbonyl group or methylene group;

~~A~~ is a direct bond, one of the divalent radicals (C₁-C₆)-alkylene, (C₃-C₇)-cycloalkylene, phenylene, phenylene-(C₁-C₆)-alkyl, phenylene-(C₂-C₆)-alkenyl or a divalent radical of a 5-membered or 6-membered, saturated or unsaturated heterocycle which can contain one or two nitrogen atoms and can be monosubstituted or disubstituted by (C₁-C₆)-alkyl or doubly bonded oxygen or sulfur, where in the radicals phenylenealkyl and phenylenealkenyl the radical R¹ is bonded to the phenylene group;

B is a divalent radical from the group consisting of (C₁-C₆)-alkylene, (C₂-C₆)-alkenylene, phenylene, phenylene-(C₁-C₃)-alkyl, (C₁-C₃)-alkylenepheryl and (C₁-C₃)-alkylenepheryl-(C₁-C₃)-alkyl, where the (C₁-C₆)-alkylene radical and the (C₂-C₆)-alkenylene radical are unsubstituted or substituted by one or more identical or different radicals from the group consisting of (C₁-C₈)-alkyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkynyl, (C₃-C₁₀)-cycloalkyl, (C₃-C₁₀)-cycloalkyl, (C₁-C₆)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₆)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl-(C₁-C₆)-alkyl optionally substituted in the heteroaryl radical;

~~E~~ is tetrazolyl, (R⁸O)₂P(O), R¹⁰OS(O)₂, R⁹NHS(O)₂, R⁶CO, R⁷CO, R¹⁰CO, HCO, R⁸O=CH₂, R⁸CO-O-CH₂, R^{8a}O-CO-O-CH₂ or (R⁸O)₂P(O)-O-CH₂;

~~R~~ is hydrogen, (C₁-C₈)-alkyl, (C₃-C₁₂)-cycloalkyl, (C₃-C₁₂)-cycloalkyl-(C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl or heteroaryl-(C₁-C₈)-alkyl optionally substituted in the heteroaryl radical, where all radicals R are independent of one another and the radicals R can be identical or different;

~~R¹~~ is hydrogen, (C₁-C₁₀)-alkyl which can optionally be mono- or polysubstituted by fluorine, (C₃-C₁₂)-cycloalkyl, (C₃-C₁₂)-cycloalkyl-(C₁-C₈)-alkyl, R²¹-((C₆-C₁₄)-aryl) optionally substituted in the aryl radical, (R²¹-((C₆-C₁₄)-aryl))-(C₁-C₈)-alkyl optionally substituted in the aryl radical, the radical Het-, Het-(C₁-C₈)-alkyl or one of the radicals X-NH-C(=NH)-R²⁰-, X¹-NH-R²⁰-, R²¹O-R²⁰-, R²¹N(R²¹)-R²⁰-, R²¹C(O)-, R²¹O-C(O)-, R²²N(R²¹)-C(O)-, R²²C(O)-N(R²¹)-, R²¹O-N=, O= and S=;

- X is hydrogen, (C₁-C₆)-alkyl, (C₁-C₆)-alkylcarbonyl, (C₁-C₆)-alkoxycarbonyl, (C₁-C₁₀)-alkylcarbonyloxy-(C₁-C₆)-alkoxycarbonyl, optionally substituted (C₆-C₁₄)-arylcarbonyl, optionally substituted (C₆-C₁₄)-aryloxycarbonyl, (C₆-C₁₄)-aryl-(C₁-C₆)-alkoxycarbonyl which can also be substituted in the aryl radical, cyano, hydroxyl, (C₁-C₆)-alkoxy, (C₆-C₁₄)-aryl-(C₁-C₆)-alkoxy which can also be substituted in the aryl radical, or amino;
- X¹ has one of the meanings of X or is R'-NH-C(=N-R''), in which R' and R'' independently of one another have the meanings of X;
- R² is hydrogen, (C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical or (C₃-C₈)-cycloalkyl;
- R³ is hydrogen, (C₁-C₁₀)-alkyl which can optionally be mono- or polysubstituted by fluorine, optionally substituted (C₆-C₁₄)-aryl; (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl, heteroaryl-(C₁-C₈)-alkyl optionally substituted in the heteroaryl radical, (C₃-C₈)-cycloalkyl, (C₃-C₈)-cycloalkyl-(C₁-C₈)-alkyl, (C₆-C₁₂)-bicycloalkyl, (C₆-C₁₂)-bicycloalkyl-(C₁-C₈)-alkyl, (C₆-C₁₂)-tricycloalkyl, (C₆-C₁₂)-tricycloalkyl-(C₁-C₈)-alkyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkynyl, R¹¹NH, CON(CH₃)R⁴, CONHR⁴, COOR²¹, COOR¹⁵, CON(CH₃)R¹⁵ or CONHR¹⁵;
- R⁴ is hydrogen or (C₁-C₁₀)-alkyl which is unsubstituted or is mono- or polysubstituted by identical or different radicals from the group consisting of hydroxyl, (C₁-C₈)-alkoxy, R⁵, optionally substituted (C₃-C₈)-cycloalkyl, hydroxycarbonyl, aminocarbonyl, mono- or di-((C₁-C₁₀)-alkyl)-aminocarbonyl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkoxycarbonyl which can also be substituted in the aryl radical, (C₁-C₈)-alkoxycarbonyl, R⁶-CO, R⁷-CO, tetrazolyl, trifluoromethyl;
- R⁵ is optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, or a radical of an optionally substituted monocyclic or bicyclic, 5-membered to 12-membered heterocyclic ring which can be aromatic, partially saturated or completely saturated and which can contain one, two or three identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur;
- R⁶ is the radical of a natural or unnatural amino acid, imino acid, optionally

N-(C₁-C₈)-alkylated or N-((C₆-C₁₄)-aryl-(C₁-C₈)-alkylated) azaamino acid which can also be substituted in the aryl radical, or the radical of a dipeptide, tripeptide or tetrapeptide, and their esters and amides, in which free functional groups can be protected by protective groups customary in peptide chemistry and in which the nitrogen atoms in the amide bonds in the group R⁸-CO can carry a radical R as a substituent;

R⁷ is the radical of a 5-membered to 10-membered, saturated monocyclic or polycyclic heterocycle bonded via a nitrogen atom, which can contain one, two, three or four identical or different additional ring heteroatoms from the group consisting of oxygen, nitrogen and sulfur and which can optionally be substituted on carbon atoms and on additional ring nitrogen atoms, in which additional ring nitrogen atoms can carry identical or different radicals from the group consisting of hydrogen, R^h, HCO, R^hCO, R^hO-CO, HO-CO-(C₁-C₄)-alkyl and R^hO-CO-(C₁-C₄)-alkyl as substituents and R^h is (C₁-C₈)-alkyl, (C₃-C₈)-cycloalkyl, (C₃-C₈)-cycloalkyl-(C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl or (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical;

~~R⁸ is hydrogen, (C₁-C₁₀)-alkyl, optionally substituted (C₆-C₁₄)-aryl or (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl which can also be substituted in the aryl radical, where the radicals R⁸ are independent of one another and can be identical or different;~~

R^{8a} independently of R⁸ has one of the meanings of R⁸ with the exception of hydrogen;

R⁹ is hydrogen, aminocarbonyl, (C₁-C₁₀)-alkylaminocarbonyl, (C₃-C₈)-cycloalkylaminocarbonyl, optionally substituted (C₆-C₁₄)-arylaminocarbonyl, (C₁-C₁₀)-alkyl, optionally substituted (C₆-C₁₄)-aryl or (C₃-C₈)-cycloalkyl;

~~R¹⁰ is hydroxy, (C₁-C₁₀)-alkoxy, (C₆-C₁₄)-aryl-(C₁-C₈)-alkoxy which can also be substituted in the aryl radical, optionally substituted (C₆-C₁₄)-aryloxy, (C₁-C₈)-alkylcarbonyloxy-(C₁-C₆)-alkoxy, (C₆-C₁₄)-arylcarbonyloxy-(C₁-C₆)-alkoxy, optionally substituted in the aryl radical, (C₆-C₁₄)-aryl-(C₁-C₆)-alkylcarbonyloxy-(C₁-C₆)-alkoxy, optionally substituted in the aryl radical, (C₁-C₈)-alkoxycarbonyloxy-(C₁-C₆)-alkoxy, (C₆-C₁₄)-aryloxycarbonyloxy-(C₁-C₆)-alkoxy optionally substituted in the aryl radical, (C₆-C₁₄)-aryl-(C₁-C₆)-~~

alkoxycarbonyloxy-(C₁-C₆)-alkoxy, optionally substituted in the aryl radical, amino, mono- or di-((C₁-C₁₀)-alkyl)-amino or R⁸R⁸N-CO-(C₁-C₆)-alkoxy, in which the radicals R⁸ are independent of one another and can be identical or different;

- 5 R¹¹ is hydrogen, R^{12a}, R^{12a}-CO, H-CO, R^{12a}-O-CO, R^{12b}-CO, R^{12b}-CS, R^{12a}-S(O)₂ or R^{12b}-S(O)₂;
- R^{12a} is (C₁-C₁₀)-alkyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkynyl, (C₃-C₁₂)-cycloalkyl, (C₃-C₁₂)-cycloalkyl-(C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, optionally substituted
- 10 heteroaryl, heteroaryl-(C₁-C₈)-alkyl optionally substituted in the heteroaryl radical, or the radical R¹⁵;
- R^{12b} is amino, di-((C₁-C₁₀)-alkyl)-amino or R^{12a}-NH;
- R¹³ is hydrogen, (C₁-C₆)-alkyl which can optionally be mono- or polysubstituted by fluorine, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₆)-alkyl
- 15 optionally substituted in the aryl radical, (C₃-C₈)-cycloalkyl or (C₃-C₈)-cycloalkyl-(C₁-C₆)-alkyl;
- R¹⁵ is R¹⁶-(C₁-C₆)-alkyl or R¹⁶;
- R¹⁶ is a 6-membered to 24-membered, bicyclic or tricyclic radical which is
- 20 saturated or partially unsaturated and which can also contain one, two, three or four identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of (C₁-C₄)-alkyl and oxo;
- R²⁰ is a direct bond or a divalent (C₁-C₆)-alkylene radical;
- R²¹ is hydrogen, (C₁-C₈)-alkyl, (C₃-C₁₂)-cycloalkyl, (C₃-C₁₂)-cycloalkyl-(C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally
- 25 substituted in the aryl radical, the radical Het- or Het-(C₁-C₈)-alkyl, in which alkyl radicals can be monosubstituted or polysubstituted by fluorine and the radicals R²¹, if they occur more than once, are independent of one another and can be identical or different;
- 30 R²² is R²¹-, R²¹O-, R²¹N(R²¹)-, R²¹C(O)-, R²¹O-C(O)-, R²¹N(R²¹)-C(O)-, R²¹N(R²¹)-C(=N(R²¹))- or R²¹C(O)-N(R²¹)-;

R^{30} is one of the radicals $R^{32}(R)N-CO-N(R)-R^{31}$, $R^{32}(R)N-CS-N(R)-R^{31}$

$R^{32}(R)N-S(O)_n-N(R)-R^{31}$, $R^{32}-CO-N(R)-R^{31}$, $R^{32}-CS-N(R)-R^{31}$,

$R^{32}-S(O)_n-N(R)-R^{31}$, $R^{32}(R)N-CO-R^{31}$, $R^{32}(R)N-CS-R^{31}$, $R^{32}(R)N-S(O)_n-R^{31}$,

$R^{32}-CO-R^{31}$, $R^{32}-CS-R^{31}$, $R^{32}-S(O)_n-R^{31}$ or $R^{12a}-O-CO-N(R)-R^{31}$, where R^{30}

5 cannot be $R^{32}-CO-N(R)-R^{31}$ if at the same time W is $R^1-A-C(R^{13})$, A is a direct bond and R^1 and R^{13} are hydrogen;

R^{31} is the divalent radical $-R^{33}-R^{34}-R^{35}-R^{36}-$, where R^{36} is bonded to the nitrogen atom in the imidazolidine ring in the formula I;

R^{32} is hydrogen, (C_1-C_8) -alkyl, which can optionally be substituted by 1 to 8
10 fluorine atoms, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, (C_3-C_{12}) -cycloalkyl, (C_3-C_{12}) -cycloalkyl- (C_1-C_8) -alkyl, (C_6-C_{12}) -bicycloalkyl, (C_6-C_{12}) -bicycloalkyl- (C_1-C_8) -alkyl, (C_6-C_{12}) -tricycloalkyl, (C_6-C_{12}) -tricycloalkyl- (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl or heteroaryl- (C_1-C_8) -alkyl
15 optionally substituted in the heteroaryl radical;

R^{33} is a direct bond or a divalent (C_1-C_6) -alkylene radical;

R^{34} is a divalent radical from the group consisting of (C_1-C_8) -alkylene, (C_3-C_{12}) -cycloalkylene, (C_6-C_{12}) -bicycloalkylene, (C_6-C_{12}) -tricycloalkylene, optionally substituted (C_6-C_{14}) -arylene and optionally substituted heteroarylene;

20 R^{35} is a direct bond or a divalent (C_1-C_8) -alkylene radical;

R^{36} is a direct bond, the group $-CO-$ or the group $-S(O)_n-$;

Het is a radical of a monocyclic or polycyclic, 4-membered to 14-membered, aromatic or nonaromatic ring which contains 1, 2, 3 or 4 identical or different heteroatoms from the group consisting of N, O and S as ring members and can
25 optionally be substituted by one or more identical or different substituents;

e and h independently of one another are 0 or 1;

n is 1 or 2, where the numbers n, if they occur more than once, are independent of one another and can be identical or different;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their

30 physiologically tolerable salts.

R^8 is hydrogen, (C_1-C_6) -alkyl or phenyl- (C_1-C_4) -alkyl optionally substituted in the phenyl radical,

R^{10} is hydroxyl, (C_1-C_8) -alkoxy, (C_6-C_{10}) -aryl- (C_1-C_6) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{10}) -aryloxy, (C_1-C_6) -alkylcarbonyloxy- (C_1-C_6) -alkoxy, (C_1-C_6) -alkoxycarbonyloxy- (C_1-C_6) -alkoxy, amino, mono- or di- $((C_1-C_6)$ -alkyl)-amino, aminocarbonyl- (C_1-C_6) -alkoxy or (mono- or di- $((C_1-C_6)$ -alkyl)-amino)-carbonyl- (C_1-C_6) -alkoxy;

R^{11} is hydrogen, R^{12a} , R^{12a} -CO, R^{12a} -O-CO, R^{12b} -CO, or R^{12a} -S(O)₂;

R^{12a} is (C_1-C_8) -alkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, (C_5-C_6) -cycloalkyl, (C_5-C_6) -cycloalkyl- (C_1-C_4) -alkyl, optionally substituted (C_6-C_{10}) -aryl, (C_6-C_{10}) -aryl- (C_1-C_4) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl, heteroaryl- (C_1-C_4) -alkyl optionally substituted in the heteroaryl radical, or the radical R^{15} ;

R^{12b} is amino, di- $((C_1-C_8)$ -alkyl)-amino or R^{12a} -NH;

R^{13} is hydrogen or (C_1-C_6) -alkyl;

R^{15} is R^{16} - (C_1-C_6) -alkyl or R^{16} ;

R^{16} is a 6-membered to 12-membered, bicyclic or tricyclic radical which is saturated or partially unsaturated and which can also contain one, two, three or four identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of (C_1-C_4) -alkyl and oxo;

R^{20} is a direct bond or methylene;

R^{21} is hydrogen, (C_1-C_6) -alkyl, optionally substituted (C_6-C_{10}) -aryl, (C_6-C_{10}) -aryl- (C_1-C_2) -alkyl optionally substituted in the aryl radical, the radical Het- or Het- (C_1-C_2) -alkyl, where alkyl radicals can be monosubstituted to tetrasubstituted by fluorine and the radicals R^{21} , if they occur more than once can be identical or different;

R^{30} is one of the radicals $R^{32}(R)N-CO-N(R)-R^{31}$ or $R^{32}(R)N-CS-N(R)-R^{31}$,

R^{31} is a divalent radical from the group consisting of (C_1-C_6) -alkylene, optionally substituted (C_6-C_{10}) -arylene, (C_6-C_{10}) -arylene- (C_1-C_4) -alkyl optionally substituted in the arylene radical, (C_5-C_6) -cycloalkylene, (C_5-C_6) -

cycloalkylene-(C₁-C₄)-alkyl, optionally substituted heteroarylene or heteroarylene-(C₁-C₄)-alkyl optionally substituted in the heteroarylene radical, where in the case of the arylenealkyl radical, of the cycloalkylenealkyl radical and of the heteroarylenealkyl radical the alkyl group is bonded to the nitrogen atom in the imidazolidine ring in the formula I;

R³² is hydrogen, (C₁-C₆)-alkyl which can optionally be substituted by 1 to 6 fluorine atoms, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₅-C₆)-cycloalkyl, (C₅-C₆)-cycloalkyl-(C₁-C₄)-alkyl, optionally substituted (C₆-C₁₀)-aryl, (C₆-C₁₀)-aryl-(C₁-C₄)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl or heteroaryl-(C₁-C₄)-alkyl optionally substituted in the heteroaryl radical;

Het is a radical of a monocyclic or polycyclic, 5-membered to 10-membered, aromatic or nonaromatic ring which contains 1 or 2 identical or different heteroatoms from the group consisting of N and O as ring members and which can optionally be substituted by one or more, identical or different substituents;

e and h independently of one another are 0 or 1;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts.

5. A compound of the formula I as claimed in one or more of claims 1 to 4, in which W has a meaning other than CH₂, in all its stereoisomeric forms and mixtures thereof in all ratios, or its physiologically tolerable salts.

6. A compound of the formula I as claimed in one or more of claims 1 to 5, in which B is unsubstituted methylene or methylene which is substituted by (C₁-C₆)-alkyl or (C₃-C₆)-cycloalkyl-(C₁-C₂)-alkyl, in all its stereoisomeric forms and mixtures thereof in all ratios, or its physiologically tolerable salts.


7. A compound of the formula I as claimed in one or more of claims 1 to 6, in which R³⁰ is one of the radicals R³²(R)N-CO-N(R)-R³¹ or R³²(R)N-CS-N(R)-R³¹, in all its

stereoisomeric forms and mixtures thereof in all ratios, or its physiologically tolerable salts.


8. A compound of the formula I as claimed in one or more of claims 1 to 7, in which R^{30} is the radical R^{32} -NH-CO-NH- R^{31} and, therein, R^{31} is the divalent radical $-(1,4\text{-phenylene})\text{-CH}_2\text{-}$ in which the methylene group is bonded to the nitrogen atom in the imidazolidine ring, and R^{32} is unsubstituted or substituted phenyl, in all its stereoisomeric forms and mixtures thereof in all ratios, or its physiologically tolerable salts.

9. A compound of the formula I as claimed in one or more of claims 1 to 8, in which W has a meaning other than CH_2 , B is unsubstituted methylene or methylene which is substituted by $(\text{C}_1\text{-C}_6)\text{-alkyl}$ or $(\text{C}_3\text{-C}_6)\text{-cycloalkyl}$, R^{30} is the radical $R^{32}\text{NH-CO-NH-}R^{31}$, R^{31} is the divalent radical $-(1,4\text{-phenylene})\text{-CH}_2\text{-}$ in which the methylene group is bonded to the nitrogen atom in the imidazolidine ring, R^{32} is unsubstituted or substituted phenyl, and the group $\text{-NR-[C(R)(R)]}_6\text{-C(R}^2\text{)(R}^3\text{)-[C(R)(R)]}_h\text{-E}$ in the formula I is the group $\text{-NH-CH(R}^3\text{)-CH}_2\text{-E}$, in all its stereoisomeric forms and mixtures thereof in all ratios, or its physiologically tolerable salts.

10. A process for the preparation of compounds of the formula I as claimed in one or more of claims 1 to 9, which comprises carrying out a fragment condensation of a compound of the formula II



with a compound of the formula III,



- 5 where, in the formulae II and III, the groups W, Y, B, E, R, R², R³ and R³⁰ as well as e and h are defined as indicated in claims 1 to 9 or alternatively functional groups can be present in protected form or in the form of precursors, and where G is hydroxycarbonyl, (C₁-C₆)-alkoxycarbonyl or activated carboxylic acid derivatives.
- 10 11. A compound of the formula I as claimed in one or more of claims 1 to 9 and/or its physiologically tolerable salts for use as a pharmaceutical.
12. A pharmaceutical preparation which contains one or more compounds of the formula I as claimed in one or more of claims 1 to 9 and/or its physiologically
15 tolerable salts and a pharmaceutically innocuous excipient.
13. A compound of the formula I as claimed in one or more of claims 1 to 9 and/or its physiologically tolerable salts for use as antiinflammatories.
- 20 14. A compound of the formula I as claimed in one or more of claims 1 to 9 and/or its physiologically tolerable salts for use in the therapy or prophylaxis of arthritis, or rheumatoid arthritis, of polyarthritis, of inflammatory bowel disease, of systemic lupus erythematosus, of multiple sclerosis or of inflammatory disorders of the central nervous system.
- 25 15. A compound of the formula I as claimed in one or more of claims 1 to 9 and/or its physiologically tolerable salts for use in the therapy or prophylaxis of asthma or allergies.
- 30 16. A compound of the formula I as claimed in one or more of claims 1 to 9 and/or its physiologically tolerable salts for use in the therapy or prophylaxis of cardiovascular